Accelerate Your
Cell & Gene Therapy
Contract Development & Manufacturing
Accelerate Your
Cell & Gene Therapy
Contract Development & Manufacturing
At NecstGen, we enable the next generation of therapies by offering development support and GMP production of Cell and Gene Therapies. Together, we challenge today’s possibilities and enable the unthinkable.
The Scientist behind HEK293
While working in the Netherlands in the 1970s, genetic engineer and virologist Frank Graham developed the Calcium Phosphate Transfection technique and created the HEK293 cell line, now a cornerstone of gene therapy, vaccine development, and viral vector production.
Are you bringing a Gene or Cell Therapy to patients? We can help.
Solely dedicated to the field of Cell and Gene Therapy, we provide capacity, expertise, and services tailored accelerate the development of your therapy to the clinic and beyond. Our approach is characterised by open and transparent communication, fostering a culture of collaboration and knowledge sharing.
Cell Therapies
NecstGen offers services for Cell Therapy and ex vivo Cell Therapy process and analytical development and manufacturing.
Viral Vectors
NecstGen provides a high-caliber process for Viral Vector manufacturing for your Gene Therapy.
Consultancy & Support
NecstGen offers consultancy and support throughout all stages of therapy development .
“At NecstGen, we offer process development solutions, contract preclinical/ GMP manufacturing and consultancy for Cell and Gene Therapies to clinicians, academic, small, medium, and large commercial organisations worldwide. We have a focused expert team and bespoke facility to offer you the support and capacity needed to deliver your therapy to patients.
We enable the next generation of therapies by translating research programs into health solutions for patients.“
News & Insights
Join The CGT Circle in Leiden on 24 November
Join The CGT Circle in Leiden on 24 November for an afternoon of talks, discussion and networking with women working across cell and gene therapy, from research and regulatory affairs to therapy development.
Niek Visarius joins NecstGen as Interim CEO and Transition Manager
Leading NecstGen’s integration into LUMC while ensuring continuity across its programs and services.
Webinar Replay: ‘Case Study: Development of a Scalable LV Production Platform’
Learn how structured process development can support scalable lentiviral vector production.
